Brief: Hydration Pharmaceuticals Posts HY EBITDA Loss $3.6M
31/08/2023 02:26
Aug 31 (Reuters) - Hydration Pharmaceuticals Co Ltd
HPC.AX :
* HY EBITDA LOSS US$3.6M VERSUS OF LOSS OF US$5.2M
* HY NET REVENUE US$5.3M, 28% GROWTH ON PCP
Source text for Eikon: ID:nASX9LC2hH
Further company coverage: HPC.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hydration Pharmaceuticals
See all newsBrief: Hydration Pharmaceuticals Launches Pro Rata Entitlement Offer To Raise Up To A$1.43 MLN
Australia's Hydration Pharmaceuticals soars on upbeat monthly sales
Australia's Hydration Pharmaceuticals soars 144% on asset sale to US co
Brief: Hydration Pharmaceuticals Announces Divesture Of Hydralyte's Non-US Assets
Brief: Hydration Pharmaceuticals Says Adem Karafili Appointed Non-Executive Chairman